Egis intensifies its acquisition strategy

6 November 2017
servier-big

Egis Pharmaceuticals, French independent drugmaker Servier’s generics company, has acquired Sorbifer’s (ferrous sulfate + ascorbic acid) product rights from AstraZeneca (LSE: AZN). The transaction reinforces Egis’ position on its key markets.

Egis, of which Servier gained full ownership in a deal worth around $483 million in 2013, has already been producing, distributing and promoting Sorbifer in 18 Central and Eastern Europe (CEE) and Commonwealth of Independent States (CIS) markets since 1985 under a licence agreement with Anglo-Swedish pharma major AstraZeneca. The product has become one of the major brands of Egis, the fifth largest of the company.

Sorbifer is an anti-anemia prescription drug, which has a strong position in the CEE and CIS markets, particularly in Russia and Poland.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical